Cencora, Inc. COR reported first-quarter fiscal 2025 adjusted earnings per share (EPS) of $3.73, which beat the Zacks Consensus Estimate of $3.50 by 6.6%. The bottom line also improved 13.7% year over ...

U.S. farmers and various trade groups are very apprehensive about not only the potential negative impacts of tariffs on the U ...

Young machers without college educations power a cycle of hard work and dues-paying in Lakewood real estate, but the local ...

Prior to analysis, recorded medication doses were converted to standardised equivalents using conversion ... median age 53 years) (table 1), of whom 82% (n=45) used illicit opioids. Opioids were used ...

Distribution of prescribed opioid analgesics is lower in majority non-White versus majority White communities across all levels of socioeconomic deprivation.

More New Yorkers received scripts for buprenorphine, a med used to treat opioid addiction, amid fight against record-high ...

Analyst is bullish on Vertex Pharmaceuticals, citing FDA approval for JOURNAVX and strong earnings growth potential in 2025.

The FDA on Thursday approved a new class of pain medication that provides an alternative to opioids. It will be sold under ...

For the first time in two decades, the FDA has approved a new class of non-opioid pain medication, offering an alternative to addictive opioids for patients seeking pain relief. The drug ...

For the first time in two decades, the Food and Drug Administration (FDA) has approved a new class of medication that provides an alternative to addictive opioids for patients looking to manage ...

WASHINGTON (AP) — Federal officials on Thursday approved a new type of pain pill designed to eliminate the risks of addiction and overdose associated with opioid medications like Vicodin and ...

The FDA has approved Journavx, a pain medication, offering a safer alternative to opioids. Learn about its benefits and side ...